The FORTITUDE Study
The FORTITUDE Study is a Phase I multicenter, open-label, non randomized first-in-human clinical trial of NG-350A in patients with metastatic or advanced epithelial tumors. The FORTITUDE study is expected to enroll up to 125 patients across multiple clinical study sites. Phase 1a of the study will assess the safety, tolerability and dose of NG-350A and will enroll patients at study sites in the United States, led by MD Anderson Cancer Center. Phase 1b of the study will evaluate NG-350A in expansion cohorts in patients with specific metastatic or advanced tumors.
For more information about this trial and participating centres, please follow the link:
The SPICE Study
The SPICE Study (Study of PD-1 Inhibition in Combination with Enadenotucirev) is run by PsiOxus in a clinical trial collaboration with Bristol-Myers Squibb.
The SPICE Study is a Phase I multicenter, open label, non-randomized study of enadenotucirev administered in combination with nivolumab in patients with metastatic or advanced solid tumors (with a focus on non-small cell lung cancer, colorectal cancer and squamous cell cancer of the head and neck) not responding to standard therapy. This study is currently recruiting patients in the USA and it is planned to recruit patients in Spain to the next phase of the study.
For more information about this trial and participating centres, please follow these links:
ClinicalTrials.gov Poster presented at ASCO 2017